RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VBI Vaccines Stock

VBI Vaccines Revenue 2024

VBI Vaccines Revenue

13.1 M USD

Ticker

VBIV

ISIN

CA91822J1030

WKN

A2AJ0L

In 2024, VBI Vaccines's sales reached 13.1 M USD, a 50.9% difference from the 8.68 M USD sales recorded in the previous year.

The VBI Vaccines Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2026e60.02-6,37
2025e34.81-10,99
2024e13.1-29,20
20238.68-44,06
20221.08-943,52
20210.63-1609,52
20201.06-765,09
20192.22-255,86
20183.36-34,23
20170.87-497,70
20160.55-567,27
20150.96-291,67
2014--
2013--
2012--
2011--
2010--
2009--
2008--
2007--
2006--
2005--
2004--

VBI Vaccines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into VBI Vaccines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by VBI Vaccines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects VBI Vaccines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of VBI Vaccines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into VBI Vaccines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing VBI Vaccines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on VBI Vaccines’s growth potential.

VBI Vaccines Revenue, EBIT and net profit per share

DateVBI Vaccines RevenueVBI Vaccines EBITVBI Vaccines Net Income
2026e60.02 M undefined-15.6 M undefined-6.73 M undefined
2025e34.81 M undefined-20.42 M undefined-8.19 M undefined
2024e13.1 M undefined-38.26 M undefined-35.98 M undefined
20238.68 M undefined-55.31 M undefined-93.84 M undefined
20221.08 M undefined-81.82 M undefined-113.3 M undefined
2021630,000 undefined-68.03 M undefined-69.75 M undefined
20201.06 M undefined-43.62 M undefined-46.23 M undefined
20192.22 M undefined-46.11 M undefined-54.81 M undefined
20183.36 M undefined-54.11 M undefined-63.6 M undefined
2017870,000 undefined-37.28 M undefined-39 M undefined
2016550,000 undefined-24.85 M undefined-23.21 M undefined
2015960,000 undefined-10.96 M undefined-14.76 M undefined
20140 undefined-5.14 M undefined-73.42 M undefined
20130 undefined-5.55 M undefined-4.82 M undefined
20120 undefined-7.5 M undefined-6.76 M undefined
20110 undefined-13.68 M undefined-13.22 M undefined
20100 undefined-24.22 M undefined-24.24 M undefined
20090 undefined-680,000 undefined-670,000 undefined
20080 undefined-290,000 undefined-290,000 undefined
20070 undefined-570,000 undefined-560,000 undefined
20060 undefined-370,000 undefined-210,000 undefined
20050 undefined-370,000 undefined-360,000 undefined
20040 undefined-120,000 undefined-50,000 undefined

VBI Vaccines stock margins

The VBI Vaccines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VBI Vaccines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VBI Vaccines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the VBI Vaccines's sales revenue. A higher gross margin percentage indicates that the VBI Vaccines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the VBI Vaccines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the VBI Vaccines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the VBI Vaccines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the VBI Vaccines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the VBI Vaccines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

VBI Vaccines Margin History

VBI Vaccines Gross marginVBI Vaccines Profit marginVBI Vaccines EBIT marginVBI Vaccines Profit margin
2026e-44.06 %-26 %-11.21 %
2025e-44.06 %-58.66 %-23.53 %
2024e-44.06 %-292.02 %-274.65 %
2023-44.06 %-637.08 %-1,080.87 %
2022-943.52 %-7,575.93 %-10,490.74 %
2021-1,609.52 %-10,798.41 %-11,071.43 %
2020-765.09 %-4,115.09 %-4,361.32 %
2019-255.86 %-2,077.03 %-2,468.92 %
2018-34.23 %-1,610.42 %-1,892.86 %
2017-497.7 %-4,285.06 %-4,482.76 %
2016-567.27 %-4,518.18 %-4,220 %
2015-291.67 %-1,141.67 %-1,537.5 %
2014-44.06 %0 %0 %
2013-44.06 %0 %0 %
2012-44.06 %0 %0 %
2011-44.06 %0 %0 %
2010-44.06 %0 %0 %
2009-44.06 %0 %0 %
2008-44.06 %0 %0 %
2007-44.06 %0 %0 %
2006-44.06 %0 %0 %
2005-44.06 %0 %0 %
2004-44.06 %0 %0 %

VBI Vaccines Aktienanalyse

What does VBI Vaccines do?

VBI Vaccines Inc is a company focused on the development and commercialization of vaccines. The company was founded in Canada in 2001 and is currently headquartered in Cambridge, Massachusetts, USA. Its business model is based on research, development, and marketing of vaccines for the prevention and treatment of infectious diseases. VBI Vaccines works closely with academic institutions, government agencies, biotech companies, and pharmaceutical companies to advance its products. The company offers a wide range of products, including prophylactic vaccines against infectious diseases such as Hepatitis B, Cytomegalovirus, Japanese encephalitis, and uncontrolled HIV infections. It is also working on the development of therapeutic vaccines against cancer. One of VBI Vaccines' key divisions is the hepatitis B vaccines, with its innovative platform called Sci-B-Vac offering higher protection and longer effectiveness than other available vaccines. VBI Vaccines has also developed a prophylactic platform called LPV™ technology (Lipid Particle Vaccine) which facilitates vaccine production by being easy to manufacture, stable, and transportable. This technology also allows for rapid development of vaccines against new infectious diseases. The company is also involved in the clinical development of therapeutic vaccines against cancer, aiming to mobilize and activate the body's immune system against cancer cells. Successful clinical studies have been conducted for therapy vaccines against glioblastomas (a type of brain tumor) and rhabdomyosarcomas (a rare tumor). Overall, VBI Vaccines has a promising research path for the development of vaccines for the prevention and treatment of infectious diseases and cancer. The company is innovative and relies on technologies that improve vaccine effectiveness and ease their production. VBI Vaccines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding VBI Vaccines's Sales Figures

The sales figures of VBI Vaccines originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing VBI Vaccines’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize VBI Vaccines's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in VBI Vaccines’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about VBI Vaccines stock

How much revenue did VBI Vaccines generate this year?

VBI Vaccines has achieved a revenue of 13.1 M USD this year.

How much was the turnover of the company VBI Vaccines compared to the previous year?

The revenue of VBI Vaccines has increased by 50.9% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of VBI Vaccines?

The revenue of VBI Vaccines is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of VBI Vaccines measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of VBI Vaccines so important for investors?

The revenue of VBI Vaccines is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does VBI Vaccines pay?

Over the past 12 months, VBI Vaccines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, VBI Vaccines is expected to pay a dividend of 0 USD.

What is the dividend yield of VBI Vaccines?

The current dividend yield of VBI Vaccines is .

When does VBI Vaccines pay dividends?

VBI Vaccines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of VBI Vaccines?

VBI Vaccines paid dividends every year for the past 0 years.

What is the dividend of VBI Vaccines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is VBI Vaccines located?

VBI Vaccines is assigned to the 'Health' sector.

Wann musste ich die Aktien von VBI Vaccines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VBI Vaccines from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did VBI Vaccines pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of VBI Vaccines in the year 2023?

In the year 2023, VBI Vaccines distributed 0 USD as dividends.

In which currency does VBI Vaccines pay out the dividend?

The dividends of VBI Vaccines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VBI Vaccines

Our stock analysis for VBI Vaccines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VBI Vaccines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.